Autoimmune hepatitis and liver transplantation:Indications,and recurrent and de novo autoimmune hepatitis
作者机构：Department of Gastroenterology and Transplant HepatologyInonu University Faculty of MedicineMalatya 44280Turkey Department of GastroenterologyAdiyaman Education and Research HospitalAdıyaman 04120Turkey Liver Transplant InstituteInonu UniversityMalatya 44280Turkey
出 版 物：《World Journal of Transplantation》 (世界移植杂志)
年 卷 期：2022年第12卷第3期
页 面：59-64页
主 题：Liver transplantation Autoimmune hepatitis Recurrence autoimmune hepatitis De novo autoimmune hepatitis
摘 要：Autoimmune hepatitis is a chronic inflammatory disease of the liver that is characterized by circulating autoantibodies and elevated serum globulin levels.Liver transplantation may be required for patients with acute liver failure,decompensated cirrhosis,and hepatocellular carcinoma.Recurrence is defined as development of the same disease in the allograft following liver transplantation.Autoimmune hepatitis recurs in 36%-68%of the recipients 5 years after liver transplantation.De novo autoimmune hepatitis is the development of autoimmune hepatitis like clinical and laboratory characteristics in patients who had undergone liver transplantation for causes other than autoimmune hepatitis.Diagnostic work up for recurrent and de novo autoimmune hepatitis is similar to the diagnosis of the original disease,and it is usually difficult.Predniso(lo)ne with or without azathioprine is the main treatment for recurrent and de novo autoimmune hepatitis.Early diagnosis and treatment are vital for patient prognosis because de novo autoimmune hepatitis and recurrent autoimmune hepatitis cause graft loss and result in subsequent retransplantation if medical treatment fails.
维普期刊数据库